Latest posts
-
COVID-19 vaccine with IPD nanoparticles meets Phase 1/2 trial goals
This report was written and translated into English by SK bioscience. (Image: SK bioscience) SK bioscience (CEO Jae-yong Ahn) announced on November 4th that the company has confirmed a positive immune response and safety in the final analysis result of the phase I/II clinical trial of the COVID-19 vaccine candidate,…
-
Baker lab joins USAID’s $125M project to detect emerging viruses
To better identify and prevent future pandemics, the University of Washington has become a partner in a five-year global, collaborative agreement with the U.S. Agency for International Development. The newly launched Discovery & Exploration of Emerging Pathogens – Viral Zoonoses, or DEEP VZN project, has approximately $125 million in anticipated…
-
Stephanie Berger wins additional WRF translational funding
Washington Research Foundation (WRF) has awarded a $700,000 phase three technology commercialization grant to Stephanie Berger, Ph.D., to support the development of an oral biologic for inflammatory bowel disease (IBD). Berger, a translational investigator at the Institute for Protein Design, received two previous grants totaling $300,500 from WRF for this…
-
On the passing of Tachi Yamada
Tadataka “Tachi” Yamada MD, KBE served as the Advisory Board Chair of our Institute since its founding almost ten years ago. His tremendous mentorship helped us in innumerable ways to grow from a single-PI Institute founded by David Baker to a group of five faculty and almost 200 scientists and…
-
RoseTTAFold: Accurate protein structure prediction accessible to all
Today we report the development and initial applications of RoseTTAFold, a software tool that uses deep learning to quickly and accurately predict protein structures based on limited information. Without the aid of such software, it can take years of laboratory work to determine the structure of just one protein. With RoseTTAFold,…
-
Annual Report 2021
From our deep-learning research to our new clinical trials, we are pleased to present this overview of the progress made at the Institute for Protein Design during the past year. 2021 Annual Report
-
Dr. Roy awarded WRF translational funding
Washington Research Foundation (WRF) has awarded a $250,000 phase 2 technology commercialization grant to Anindya Roy, Ph.D., to further develop a novel miniprotein binder for the treatment of idiopathic pulmonary fibrosis (IPF). Roy, an acting instructor in David Baker’s lab at the University of Washington’s Institute for Protein Design (IPD),…
-
Two nanoparticle vaccines enter clinical trials
Two different candidate vaccines developed by researchers at the Institute for Protein Design recently entered human clinical trials. GBP510, a candidate COVID-19 vaccine, is undergoing a combined Phase 1/2 trial. Flu-Mos-v1, a candidate mosaic influenza vaccine, is undergoing Phase 1 testing. Candidate COVID-19 vaccine Our SARS-CoV-2 vaccine candidate was created…
-
Nanoparticle flu shot blocks seasonal and pandemic strains
IPD researchers together with collaborators at the National Institutes of Health have developed experimental flu shots that protect animals from a wide variety of seasonal and pandemic influenza strains. The lead vaccine candidate has entered human clinical testing at the NIH. If it proves safe and effective, these next-generation influenza…
-
George Ueda and James Lazarovits awarded WRF translational funding
The Washington Entrepreneurial Research Evaluation and Commercialization Hub (WE-REACH) has announced investments in three new awards, including one to researches at the Institute for Protein Design, to expedite early-stage product development for promising biomedical innovations. The three awards are intended to reduce skin injury from wound dressing, to treat COVID-19…